Search research articles
Contact Us
Filters
Showing results (1-10 of 107) with videos related to
Page
of 11
Sort By:
Frontiers in Pharmacology
|
June 16, 2020
Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing-Using Rifampicin as an Example
Lina Keutzer, Ulrika S H Simonsson
British Journal of Clinical Pharmacology
|
January 29, 2011
Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration
Marcus A Björnsson, Ulrika S H Simonsson
CPT: Pharmacometrics & Systems Pharmacology
|
April 25, 2022
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
Rob C Van Wijk, Ulrika S H Simonsson
Rapid Communications in Mass Spectrometry : RCM
|
January 6, 2006
Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry
Britt Jansson, Doaa Elsherbiny, Ulrika S H Simonsson
Journal of Pharmacokinetics and Pharmacodynamics
|
February 20, 2013
D optimal designs for three Poisson dose-response models
Alan Maloney, Ulrika S H Simonsson, Marloes Schaddelee
Journal of Pharmacokinetics and Pharmacodynamics
|
July 12, 2013
Model based design and analysis of phase II HIV-1 trials
Dinko Rekić, Daniel Röshammar, Ulrika S H Simonsson
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
June 12, 2003
Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma by liquid chromatography
Britt Jansson, Ulrika S H Simonsson, Michael Ashton
Journal of Clinical Pharmacology
|
October 2, 2007
Optimal adaptive design in clinical drug development: a simulation example
Alan Maloney, Mats O Karlsson, Ulrika S H Simonsson
Anesthesiology
|
February 23, 2008
Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine
Emma Boström, Margareta Hammarlund-Udenaes, Ulrika S H Simonsson
Journal of Pharmacokinetics and Pharmacodynamics
|
August 29, 2015
Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
Oskar Clewe, Mats O Karlsson, Ulrika S H Simonsson
Page
of 11
Search research articles
Search
Showing results (1-10 of 107) with videos related to
Sort By:
Page
of 11
Frontiers in Pharmacology
|
June 16, 2020
Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing-Using Rifampicin as an Example
Lina Keutzer, Ulrika S H Simonsson
British Journal of Clinical Pharmacology
|
January 29, 2011
Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration
Marcus A Björnsson, Ulrika S H Simonsson
CPT: Pharmacometrics & Systems Pharmacology
|
April 25, 2022
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
Rob C Van Wijk, Ulrika S H Simonsson
Rapid Communications in Mass Spectrometry : RCM
|
January 6, 2006
Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry
Britt Jansson, Doaa Elsherbiny, Ulrika S H Simonsson
Journal of Pharmacokinetics and Pharmacodynamics
|
February 20, 2013
D optimal designs for three Poisson dose-response models
Alan Maloney, Ulrika S H Simonsson, Marloes Schaddelee
Journal of Pharmacokinetics and Pharmacodynamics
|
July 12, 2013
Model based design and analysis of phase II HIV-1 trials
Dinko Rekić, Daniel Röshammar, Ulrika S H Simonsson
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
June 12, 2003
Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma by liquid chromatography
Britt Jansson, Ulrika S H Simonsson, Michael Ashton
Journal of Clinical Pharmacology
|
October 2, 2007
Optimal adaptive design in clinical drug development: a simulation example
Alan Maloney, Mats O Karlsson, Ulrika S H Simonsson
Anesthesiology
|
February 23, 2008
Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine
Emma Boström, Margareta Hammarlund-Udenaes, Ulrika S H Simonsson
Journal of Pharmacokinetics and Pharmacodynamics
|
August 29, 2015
Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
Oskar Clewe, Mats O Karlsson, Ulrika S H Simonsson
Page
of 11